According to a study published by Insure Insights, the global triptorelin market is estimated to grow at a CAGR of 5.9% during the forecast period. Triptorelin acts as an agonist analog of Gonadotropin-releasing hormone and reversibly repress luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is a decapeptide and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts. Triptorelin is used in the treatment of advanced prostate cancer in men. Triptorelin works by minimizing the amount of testosterone that the body produces. This effect helps to slow down or stop the growth of cancer cells and helps relieve symptoms such as painful/difficult urination. This medication is similar to a natural substance made by the body (luteinizing hormone-releasing hormone-LHRH).

Top Driver: Extended Application of Triptorelin

Triptorelin is a first-line hormonal therapy, which proved efficacy and safety in clinical trials of patients with non-metastatic and metastatic prostate cancer. Moreover, the supreme efficacy and effectiveness of triptorelin in the suppression of gonadotropin in Central Precocious Puberty (CPP) in young boys and girls is estimated to propel the triptorelin market growth. Further, comprehensive research and development activities aiming at the application of androgen deprivation therapy with triptorelin to reduce the progression of salivary gland cancer expressing androgen receptors.

Triptorelin Pamoate Segment is Expected to Witness Growth During the Forecast Period

The global triptorelin market is segmented into triptorelin pamoate, triptorelin acetate, and triptorelin embonate based on the product. The triptorelin pamoate segment is expected to dominate the market due to Triptorelin pamoate may cause a short-term (within the first two weeks of treatment) increase in testosterone serum levels. Based on the application, the market has been segmented into prostate cancer, endometriosis, salivary gland cancer, radical prostatectomy, and central precocious puberty. On the basis of end-user, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.

   The Growing Prevalence of Prostate Cancer and Salivary Gland Cancers to Benefit North America Market

Based on the region, the global triptorelin market has been segmented into North America, Europe, Asia Pacific, and SAMEA. North America holds the largest market share in the global triptorelin market. The growth is attributed to the growing prevalence of prostate cancer and salivary gland cancers. Moreover, other factors, such as the growing incidence of crucial precocious puberty among young patients below age eight and nine years and increasing changes in the lifestyle of people and their eating habits, is expected to boost the market in this region.

Players to Focus on Approval of New Product

The global triptorelin market is estimated to stay fragmented during the forecast period owing to the possible new entrants. The major market players operating in the market are Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan Pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC. There are several recent developments in the market, such as in March 2017, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK coordinated with fourteen other European regulatory agencies and approved a new indication of Decapeptyl (triptorelin). In 2016, the European Organization for Research and Treatment of Cancer with Debiopharm International SA collaborated to investigate Triptorelin to treat salivary gland cancer. Moreover, in 2017 triptorelin got approved as an adjuvant treatment in combination with tamoxifen for endocrine-responsive early stage breast cancer in the women at high risk of recurrence for those are confirmed as pre-menopausal after completion of chemotherapy.

Scope of the Report

By Product

• Triptorelin Pamoate
• Triptorelin Acetate
• Triptorelin Embonate

By Application

• Prostate cancer
• Radical Prostatectomy
• Endometriosis
• Central Precocious Puberty
• Salivary Gland Cancer

By End-User

• Hospital Pharmacy
• Online pharmacy
• Retail pharmacy

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.